Royalty Pharma EVP awarded 11,002 Class A shares
Hite Christopher reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Hite Christopher reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc executive Christopher Hite, EVP & Chairman, Partnering, received an exempt grant of 11,002 Class A Ordinary Shares on 2026-08-05 in connection with settlement of Equity Performance Awards, held indirectly through SCH Investment Partners LLC, bringing that entity’s holdings to 470,401 shares. He also holds 40,000 Class A Ordinary Shares directly, while family vehicles controlled by him hold limited partnership interests exchangeable into 866,410 additional Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,238,789 Class A Ordinary Shares, which are subject to vesting conditions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 11,002 shares
Grant/Award
2 txns
Insider
Hite Christopher
Role
EVP & Chairman, Partnering
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Ordinary Shares F1 | 11,002 | $0.00 | $0.00 |
| holding | Class A Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Class A Ordinary Shares — 470,401 shares (Indirect, By SCH Investment Partners LLC);
Class A Ordinary Shares — 40,000 shares (Direct)
Footnotes (1)
- F1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
Key Figures
Equity award granted: 11,002 Class A Ordinary Shares
Indirect Class A holdings after award: 470,401 Class A Ordinary Shares
Direct Class A holdings: 40,000 Class A Ordinary Shares
+3 more
6 metrics
Equity award granted
11,002 Class A Ordinary Shares
Exempt acquisition on 2026-08-05 in connection with settlement of Equity Performance Awards
Indirect Class A holdings after award
470,401 Class A Ordinary Shares
Held indirectly through SCH Investment Partners LLC following the reported grant
Direct Class A holdings
40,000 Class A Ordinary Shares
Direct ownership position reported as of 2026-08-05
Exchangeable via RPI US Partners 2019, LP
866,410 Class A Ordinary Shares
Family vehicles’ limited partnership interests exchangeable into Royalty Pharma Class A Ordinary Shares
Exchangeable via Class E Ordinary Shares
1,238,789 Class A Ordinary Shares
Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into Class A, subject to vesting
Transaction date
2026-08-05
Date of exempt acquisition of 11,002 Class A Ordinary Shares
Key Terms
Rule 16b-3, Equity Performance Awards, limited partnership interests, Class E Ordinary Shares
4 terms
Rule 16b-3 regulatory
"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
Equity Performance Awards financial
"acquisition of Class A Ordinary Shares in connection with the settlement of Equity Performance Awards"
limited partnership interests financial
"family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP"
An ownership stake in a limited partnership gives an investor the role of a limited partner who provides capital but does not run day-to-day operations; a separate general partner manages the business. It matters because limited partners share profits, losses, and tax benefits but generally cannot lose more than they invested and have little control or liquidity—think of it like quietly funding a small business while someone else manages it, with potential return and risk tied to the venture’s performance.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider equity award did Christopher Hite report at Royalty Pharma (RPRX)?
Christopher Hite reported an exempt grant of 11,002 Class A Ordinary Shares on 2026-08-05, received in connection with the settlement of Equity Performance Awards. The shares are held indirectly through SCH Investment Partners LLC and were reported under Rule 16b-3.
How are Christopher Hite’s indirect Royalty Pharma (RPRX) holdings structured?
Indirect holdings include 470,401 Class A Ordinary Shares held via SCH Investment Partners LLC. In addition, family vehicles controlled by Hite hold limited partnership interests and Class E Ordinary Shares that are exchangeable into 866,410 and 1,238,789 Royalty Pharma Class A Ordinary Shares, respectively.
Were Christopher Hite’s Royalty Pharma (RPRX) transactions made under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not checked, indicating the reported exempt acquisition of 11,002 Class A Ordinary Shares was not affirmatively stated to be under a Rule 10b5-1 trading plan. No separate footnote describes a pre-arranged trading arrangement.
What role do Equity Performance Awards play in this Royalty Pharma (RPRX) filing?
The 11,002-share Class A award reported by Christopher Hite reflects the settlement of Equity Performance Awards. The exempt acquisition under Rule 16b-3 indicates these shares were granted as part of equity-based compensation rather than purchased in an open-market transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
